{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field c7ce0e61-f115-4eec-934a-785d8d02be69 --><h2>How should I assess a person with suspected hyperthyroidism?</h2><!-- end field c7ce0e61-f115-4eec-934a-785d8d02be69 -->","summary":"","htmlStringContent":"<!-- begin item 04b2ff8f-f88e-4188-8303-2f79dfeaf66b --><!-- begin field e50713c9-91d9-45cd-97ba-3fcb11e815c8 --><p><strong>If a diagnosis of hyperthyroidism is <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">suspected</a>, assess the person and arrange investigations in primary care.</strong></p><ul><li><strong>Ask about:</strong><ul><li>Typical <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">symptoms</a> of hyperthyroidism and their severity and duration, including the presence of any compression symptoms.</li><li>Current or recent pregnancy. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/pre-conception-pregnancy-postpartum/\">Scenario: Pre-conception, pregnancy, and postpartum</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/\">Management</a> for more information.</li><li>Any current or recent non-thyroidal illness or other possible causes of a transiently suppressed thyroid-stimulating hormone (TSH) level. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/#interpreting-thyroid-function-tests\">Interpreting thyroid function tests</a> for more information.<ul><li>If suspected, do not check thyroid function tests (TFTs) during acute illness unless it is felt that symptoms may be due to thyroid dysfunction, as acute non-thyroidal illness is likely to affect TFT results.</li></ul></li><li>Any <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">drug treatment</a> that may affect TFTs, including levothyroxine medication or recent exposure to radioactive iodine contrast media.</li><li>Any <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/risk-factors/\">risk factors</a> associated with hyperthyroidism, such as:<ul><li>Smoking history.</li><li>Personal history of autoimmune disorders, such as type 1 diabetes mellitus or vitiligo. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/vitiligo/\">Vitiligo</a> for more information.</li><li>Family history of thyroid disease; personal or family history of hypothalamic-pituitary disease.</li></ul></li><li>Any possible features of pituitary disease, such as history of brain or metastatic cancer; headache or visual field defects.</li></ul></li><li><strong>Examine the person for:</strong><ul><li>Possible <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">signs</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">complications</a> of hyperthyroidism, including assessment of pulse, blood pressure, temperature, weight, signs of fluid overload or heart failure.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">Thyroid enlargement</a> (a goitre) and/or thyroid nodules, tenderness, and symmetry.<ul><li>A hard and irregular goitre or nodule may indicate malignancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/head-neck-cancers-recognition-referral/\">Head and neck cancers - recognition and referral</a> for more information on urgent management.</li></ul></li><li>Signs of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">Graves&#39; disease</a>, including <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">orbitopathy</a>.</li><li>Signs of other autoimmune disease such as type 1 diabetes mellitus and vitiligo. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/vitiligo/\">Vitiligo</a> for more information.</li></ul></li><li><strong>Check the serum TSH level, using clinical judgement to </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/#interpreting-thyroid-function-tests\">interpret TFT results</a><strong>,</strong> especially if TFTs do not match the clinical presentation.<ul><li>If the TSH is within the reference range, further investigations are not usually needed, as hyperthyroidism is very unlikely.<ul><li>If symptoms worsen or new symptoms develop, consider rechecking TFTs at least six weeks after the last sample.</li></ul></li></ul></li><li><strong>If the TSH level is below the normal reference range, the free thyroxine (FT4) and free triiodothyronine (FT3) levels should be measured in the same sample.</strong><ul><li>Suspect a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">overt hyperthyroidism</a> if the TSH level is low and FT4 and/or FT3 levels are raised above the normal reference ranges.</li><li>Suspect a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">subclinical hyperthyroidism</a> if the TSH level is below the normal reference range and FT3 and FT4 levels are within the normal reference range.<ul><li>Repeat TFTs 3 months after the initial result to exclude <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/#interpreting-thyroid-function-tests\">other causes</a> of a transiently suppressed TSH and to confirm the diagnosis.</li><li>If on repeat testing there is a persistently low TSH level with normal FT4 and FT3 levels, the diagnosis is confirmed.</li></ul></li></ul></li><li><strong>Consider checking additional blood tests,</strong> depending on clinical judgement, such as:<ul><li>TSH-receptor antibodies (TRAbs) if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">Graves&#39; disease</a> is suspected or the person is pregnant.</li><li>Inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">thyroiditis</a> is suspected.</li><li>Thyroid peroxidase antibodies (TPOAbs) if a woman is postpartum and a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">postpartum thyroiditis</a> is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Baseline full blood count (FBC) and liver function tests (LFTs) if antithyroid drugs are to be started. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/\">Management</a> for more information.</li></ul></li><li><strong>Arrange an ultrasound of the neck to image palpable thyroid enlargement or focal nodularity </strong>in adults with normal thyroid function if malignancy is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neck-lump/\">Neck lump</a> for more information.</li></ul><!-- end field e50713c9-91d9-45cd-97ba-3fcb11e815c8 --><!-- end item 04b2ff8f-f88e-4188-8303-2f79dfeaf66b -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"0d6b6809-ff1f-5d44-934f-11655e1aa6b9","slug":"interpreting-thyroid-function-tests","fullItemName":"Interpreting thyroid function tests","depth":3,"htmlHeader":"<!-- begin field 7db1e32c-2ad9-419b-a110-ab55014e2ff9 --><h3>Interpreting thyroid function tests</h3><!-- end field 7db1e32c-2ad9-419b-a110-ab55014e2ff9 -->","summary":null,"htmlStringContent":"<!-- begin item 9919c9ba-a448-41d7-abd0-ab55014e2f20 --><!-- begin field 3dcdb66d-8bc8-4aa6-95ab-ab55014e2ff9 --><p><strong>Be aware that thyroid function tests (TFTs) may produce misleading results in certain clinical situations, and clinical judgement should be used when interpreting results </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>]<strong>.</strong></p><ul><li>Non-thyroidal illness ('sick euthyroid syndrome')<ul><li>A wide range of acute or chronic non-thyroidal conditions, starvation, and trauma can lead to abnormal TFTs which are not due to true dysfunction of the hypothalamic-pituitary-thyroid (HPT) axis.</li><li>Thyroid-stimulating hormone (TSH) levels can be normal or low, then becomes high during recovery from acute illness. Free thyroxine (FT4) can be normal, low, or high. Free triiodothyronine (FT3) is usually low due to reduced conversion of thyroxine (T4) to triiodothyronine (T3). Abnormalities in TFTs typically resolve with resolution of the underlying illness.</li></ul></li><li>Age<ul><li>The TSH reference range broadens with age and the upper limit increases, which reflects an altered set point of the pituitary-thyroid axis. Mild TSH elevation (4.0–7.0 mU/L) may be a normal physiological adaption to ageing.</li></ul></li><li>Ethnicity<ul><li>3–4% of people of African origin have TSH levels below the TSH reference range, and levels may also be suppressed in the black non-Hispanic American population.</li></ul></li><li>Pregnancy<ul><li>There may be a physiological suppression of TSH levels in the late first trimester of pregnancy due to placental human chorionic gonadotrophin (hCG) stimulating thyroid hormone secretion, known as 'gestational transient thyrotoxicosis'. A TSH concentration of less than 0.10 mU/L may be found in up to 3% of normal healthy women in the first trimester of pregnancy. The serum T4 level usually normalizes by 14–18 weeks' gestation.</li></ul></li><li>Hyperemesis gravidarum. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/\">Nausea/vomiting in pregnancy</a> for more information.</li><li>Drugs<ul><li>A wide range of drugs may suppress serum TSH levels, such as dopamine, high-dose glucocorticoids, amphetamines, octreotide, and bromocriptine.</li><li>Drugs containing iodine may suppress TSH levels, for example amiodarone-induced hyperthyroidism typically causes a low TSH and a raised FT4 with a raised or normal FT3.</li><li>Excess exogenous levothyroxine (LT4) intake can cause thyrotoxicosis without hyperthyroidism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li></ul></li><li>Assay interference<ul><li>There may be spurious assay results due to interfering antibodies; the over-the-counter supplement biotin ingestion may cause spuriously low TSH levels and elevate T4 and T3 levels.</li></ul></li><li>Pituitary or hypothalamic insufficiency<ul><li>A TSH-secreting pituitary adenoma may present with an inappropriately normal or elevated serum TSH level associated with elevated free T4 and total T3 concentrations.</li><li>Pituitary thyroid hormone resistance syndrome is a rare condition caused by genetic mutations in the thyroid hormone receptor-beta gene. A positive family history supports the diagnosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><!-- end field 3dcdb66d-8bc8-4aa6-95ab-ab55014e2ff9 --><!-- end item 9919c9ba-a448-41d7-abd0-ab55014e2f20 -->","subChapters":[]},{"id":"33d140eb-a588-552b-8714-b76ce1a6d414","slug":"basis-for-recommendation-e89","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 2f42ba41-5acc-49e3-ac6b-3e4d03bc614c --><h3>Basis for recommendation</h3><!-- end field 2f42ba41-5acc-49e3-ac6b-3e4d03bc614c -->","summary":null,"htmlStringContent":"<!-- begin item e89bd68b-5fdb-4cc2-870c-1aedb5b73737 --><!-- begin field 21293726-850f-44f8-9f95-91e7ca1f9116 --><p>The information on the assessment of suspected hyperthyroidism is largely based on the National Institute of Health and Care Excellence (NICE) clinical guideline <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the European Thyroid Association (ETA) publications <em>G</em><em>uidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>] and <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>]; the American Thyroid Association (ATA) publications <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>] and <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>]; the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Franklyn and Boelaert, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>], on subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>], on investigating thyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>], on smoking and thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Wiersinga, 2013</a>], and a chapter in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2010</a>].</p><h4>Clinical features on history-taking</h4><ul><li>The recommendation to check for compression symptoms is important as the person may require thyroid surgery to relieve symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li><li>The recommendation to ask about current or recent pregnancy is important, as a history of pregnancy within the past six months may suggest a diagnosis of postpartum thyroiditis. In addition, the risk of relapse of Graves' disease is higher in the postpartum period [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The recommendation to assess for any non-thyroidal illness is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].<ul><li>The recommendation not to test for thyroid dysfunction during an acute illness unless it is suspected that the acute illness is due to thyroid dysfunction is based on the fact acute illness may affect the test results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul></li><li>The recommendation to assess for any drug treatments that may affect thyroid function is based on the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li><li>A history of smoking is important as it is a dose‐dependent risk factor for developing Graves' disease and Graves' orbitopathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Wiersinga, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The recommendation to ask about a personal or family history of autoimmune disease is important, as this increases the likelihood of Graves' disease, Graves' orbitopathy, and postpartum thyroiditis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. The NICE clinical guideline also notes that autoimmune disease is associated with thyroid dysfunction and justifies testing for thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul><h4>Clinical features on examination</h4><ul><li>The information on signs to assess for on examination is based on the ATA publication on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul><h4>Checking and interpreting thyroid function test (TFT) results</h4><ul><li>There is widespread agreement in the literature that serum thyroid-stimulating hormone (TSH) measurement has the highest sensitivity and specificity of any single blood test used in the evaluation of suspected thyrotoxicosis, and should be used as an initial screening test rather than direct thyroid hormone measurements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>]. The NICE clinical guideline notes that this approach should reduce unnecessary testing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li><li>CKS notes that the NICE clinical guideline does not recommend re-testing TSH levels routinely, but to arrange re-testing if initial results are euthyroid in the presence of worsening or new symptoms. NICE recommends waiting at least six weeks before re-testing TFTs, as repeating tests sooner is unlikely to provide any new information [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. </li><li>The recommendation that if the TSH level is below the reference range, free thyroxine (FT4) and free triiodothyronine (FT3) should be measured in the same sample is based on the experience and expertise of the NICE guideline development group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. This is supported by the ETA publication on Graves' hyperthyroidism, which notes that when hyperthyroidism is strongly suspected, diagnostic accuracy improves when both a serum TSH and FT4 are assessed at the time of the initial evaluation of TSH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>]. Expert opinion in a review article notes that if the TSH level is low, measurement of FT3 and FT4 allows differentiation between a diagnosis of overt and subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>The recommendation to arrange repeat TFTs after three months if subclinical hyperthyroidism is suspected is largely extrapolated from the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. It is based on the fact there is biological variation in TSH levels, which may rise with stress and transient non-thyroidal illness for example, rather than true thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. This approach is supported by the ETA guidelines on subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>], the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].<ul><li>In addition, rechecking TFTs after a time interval will allow identification of cases where suspected subclinical hyperthyroidism has progressed to overt hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li></ul><h4>Checking additional blood tests</h4><ul><li>The recommendation to consider arranging additional blood tests is based on the fact this allows more accurate identification of an underlying cause of hyperthyroidism or thyrotoxicosis, which subsequently affects specialist management decisions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li><li>The recommendation to check TSH-receptor antibodies (TRAbs) to distinguish Graves' disease from other causes of hyperthyroidism is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], the ETA guideline on Graves' hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].<ul><li>The NICE guideline notes that the diagnostic accuracy of TRAbs testing for Graves' disease was high across different cut-off values, based on limited evidence and the experience and expertise of the guideline development group.</li><li>TRAbs are 98% sensitive and 99% specific for identifying Graves' disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The ETA guideline notes measurement of TRAbs is a sensitive and specific tool for rapid and accurate diagnosis and differential diagnosis of Graves’ hyperthyroidism.</li><li>The ATA guidelines note that TRAbs can be negative in very mild Graves' disease. In addition, if there is a low titre of TRAb and a person has Graves' disease, they are more likely to go into remission.</li><li>TRAbs can predict people at risk for relapse after antithyroid drugs are stopped, and can detect fetal thyrotoxicosis in pregnant women with Graves' disease, as these antibodies readily cross the placenta [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>The ETA guideline recommends that all women with a history of autoimmune thyroid disease should have their TRAb levels measured at the first presentation of pregnancy, and notes that TRAbs are a useful predictive measure of fetal or neonatal hyperthyroidism.</li></ul></li><li>The recommendation to check inflammatory markers if subacute thyroiditis is suspected is based on expert opinion in the UK joint publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>].<ul><li>The UK joint publication notes it is important that cases of suspected thyroiditis are identified and referred for specialist management, as standard treatment with antithyroid drugs and radioiodine is ineffective and contraindicated in these people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li></ul></li><li>The recommendation to consider checking thyroid peroxidase antibodies (TPOAbs) if a woman is postpartum and postpartum thyroiditis is suspected is based on the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].<ul><li>CKS notes, however, that the NICE clinical guideline does not recommend routinely checking TPOAbs titres in adults as evidence on the diagnostic accuracy was not available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. Expert opinion in a review article also notes that results are often non-specific and less helpful than TRAbs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li>The recommendation to check baseline full blood count (FBC) and liver function tests (LFTs) if antithyroid drugs are to be started is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h4>Arranging a neck ultrasound scan</h4><ul><li>The recommendation on when to arrange an ultrasound of the neck is based on limited evidence in the NICE clinical guideline on thyroid disease, which also noted that it may be useful for the diagnosis of Graves' disease when there are palpable thyroid nodules [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul><!-- end field 21293726-850f-44f8-9f95-91e7ca1f9116 --><!-- end item e89bd68b-5fdb-4cc2-870c-1aedb5b73737 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}